All In Biotech

Drug Trial Radar · NCT05514535

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

Efficacy and Safety of Once-weekly Semaglutide S.C. 2.0 mg as Add-on to Dose-reduced Insulin Glargine vs Titrated Insulin Glargine in Participants With Type 2 Diabetes and Overweight

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 573 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

573

Actual

Start

Aug 29, 2022

Primary completion

Mar 5, 2025

Study completion Apr 9, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.

Conditions

  • Diabetes Mellitus, Type 2
  • Obesity

Interventions

  • SemaglutideDrug

    Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.

  • Insuline glargine U100 (reduced)Drug

    Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).

  • Insuline glargine U100 (titrated)Drug

    Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Haemoglobin (HbA1c) [Noninferiority]Time frame: From baseline (week 0) to end of treatment (week 40)

Locations

239 sites in 12 countries. Site status is shown where the registry gives one.

  • Shoals Primary Care

    Sheffield, Alabama

  • Lenzmeier Fam Med CCT Research

    Glendale, Arizona

  • Synexus Clinical Research US, Inc./Desert Clinical Research,

    Mesa, Arizona

  • OneLife Direct Care Inc.

    Searcy, Arkansas

  • Unity Health-Searcy Medical Center

    Searcy, Arkansas

  • San Fernando Valley Hlth Inst, LLC

    Canoga Park, California

  • Velocity Clin Res-Chula Vista

    Chula Vista, California

  • John Muir Physicians Network

    Concord, California

  • Valley Research

    Fresno, California

  • Ascada Research

    Fullerton, California

  • Providence Medical Foundation

    Fullerton, California

  • Velocity Clinical Research Huntington Park

    Huntington Park, California

  • Scripps Memorial Hospital La Jolla

    La Jolla, California

  • Velocity Clin Res San Diego

    La Mesa, California

  • First Valley Medical Group

    Lancaster, California

  • Loma Linda Univ Hlth Cr Endo

    Loma Linda, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • NRC Research Institute

    Los Angeles, California

  • Downtown LA Res Ctr. Inc.

    Los Angeles, California

  • Velocity Clin Res Los Angeles

    Los Angeles, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • San Diego Family Care_San Diego

    San Diego, California

  • Wetlin Research Associates, Inc.

    San Diego, California

  • University Clin Investigators

    Tustin, California

  • Velocity Clin Res, Denver

    Denver, Colorado

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Indago Research & Health Center Inc.

    Hialeah, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • Northeast Res Inst. Inc.

    Jacksonville, Florida

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida

  • Care-Partners-Clinical-Research, LLC

    Jacksonville, Florida

  • Suncoast Research Group, LLC

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • Elite Research Center

    Miami, Florida

  • Diverse Clinical Research Miami

    Miami, Florida

  • Reyes Clinical Research, Inc

    Miami, Florida

  • International Research Associates, LLC_Miami

    Miami, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Suncoast Clin Res Port Richey

    New Port Richey, Florida

  • Suncoast Clinical Research, Inc._New Port Richey

    New Port Richey, Florida

Showing 40 of 239 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.